Both in Biotechnology
Ginkgo Bioworks Holdings vs Prime Medicine
Over the past year DNA returned −12.9% and PRME returned +11.1%; their daily moves had a correlation of 0.42.
DNA −12.9% PRME +11.1%Growth of $1, one year, split-adjusted
| Metric | DNA | PRME |
|---|---|---|
| Price | $11.15 | $5.07 |
| Market cap | $750.5M | $918.7M |
| Today | +3.58% | +11.32% |
| 1 month | −10.2% | +44.7% |
| 6 months | +10.6% | +48.5% |
| Year to date | +34.1% | +46.0% |
| 1 year | −12.9% | +11.1% |
| Revenue growth (YoY) | −48.5% | +3.5% |
| Gross margin | 91.5% | 100.0% |
| Net margin | −231.7% | −3649.0% |
| P/E (TTM) | — | — |
| Price / sales | 6.7× | 225.6× |
| Net cash | $302.2M | $95.1M |
| Dividend yield | — | — |
| Volatility (60d) | 128.2% | 113.5% |
| Short % of float | 18.4% | 34.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).